| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 80.94 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 80.94. The average price that SAN.PA shares were previous bought at was EUR 87.044. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 333,226 (USD $391,694) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 121.1 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 121.1. The average price that MRK.DE shares were previous bought at was EUR 117.731. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 310,578 (USD $365,072) compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 114.813 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 114.813. The average price that NOVN.SW shares were previous bought at was CHF 104.297. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 260,583 (USD $327,361) compared to the previous valuation of however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 41.4044 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 41.4044. The average price that NOVO-B.CO shares were previous bought at was DKK 54.3016. The current market price is -23.8% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 2,712,160 (USD $426,853) compared to the previous valuation of Novo Nordisk A/S |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 61.55 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 61.55. The average price that ORNBV.HE shares were previous bought at was EUR 59.669. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 29,062 (USD $34,161) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 22.55 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 22.55. The average price that PHIA.AS shares were previous bought at was EUR 22.3589. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 20,543 (USD $24,147) compared to the previous valuation of Koninklijke Philips NV |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 37.99 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 37.99. The average price that QIA.DE shares were previous bought at was EUR 39.6413. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 66,481 (USD $78,146) compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 47.94 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 47.94. The average price that REC.MI shares were previous bought at was EUR 52.7383. The current market price is -9.1% lower than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 34,766 (USD $40,866) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| RO.SW - | HOLD | 0 @ CHF 351.021 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 351.021. The average price that RO.SW shares were previous bought at was CHF 304.239. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 106,134 (USD $133,332) compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 342.261 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 342.261. The average price that ROG.SW shares were previous bought at was CHF 288.914. The current market price is 18.5% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 1,189,321 (USD $1,494,103) compared to the previous valuation of |
| LONN.SW - | HOLD | 0 @ CHF 554.412 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 554.412. The average price that LONN.SW shares were previous bought at was CHF 603.713. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 310,399 (USD $389,944) compared to the previous valuation of |
| SDZ.SW - | HOLD | 0 @ CHF 60.3551 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 60.3551. The average price that SDZ.SW shares were previous bought at was CHF 46.9107. The current market price is 28.7% higher than average price they were purchased at. The value of the holding in SDZ.SW has fallen by CHF 496,748 (USD $624,047) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 44.21 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 44.21. The average price that SHL.DE shares were previous bought at was EUR 47.1994. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 51,171 (USD $60,150) compared to the previous valuation of Siemens Healthineers AG |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 13.746 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 13.746. The average price that SN.L shares were previous bought at was GBP 13.6992. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in SN.L has increased by GBP 13,203 (USD $17,666) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 28.9972 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 28.9972. The average price that SOBI.ST shares were previous bought at was SEK 26.7864. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 121,202 (USD $13,060) compared to the previous valuation of |
| SOON.SW - | HOLD | 0 @ CHF 221.124 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 221.124. The average price that SOON.SW shares were previous bought at was CHF 260.436. The current market price is -15.1% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 44,025 (USD $55,307) compared to the previous valuation of however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 240.2 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 240.2. The average price that SRT3.DE shares were previous bought at was EUR 217.069. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 32,720 (USD $38,461) compared to the previous valuation of Sartorius AG |
| STMN.SW - | HOLD | 0 @ CHF 101.503 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 101.503. The average price that STMN.SW shares were previous bought at was CHF 109.888. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 87,283 (USD $109,651) compared to the previous valuation of |
| TUB.BR - Financiere de Tubize SA | HOLD | 0 @ EUR 213 | EUR 0 | The current share valuation price of TUB.BR based on adjusted close was EUR 213. The average price that TUB.BR shares were previous bought at was EUR 210.25. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in TUB.BR has fallen by EUR 17,744 (USD $20,857) compared to the previous valuation of Financiere de Tubize SA |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 237.5 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 237.5. The average price that UCB.BR shares were previous bought at was EUR 189.972. The current market price is 25.0% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 67,451 (USD $79,286) compared to the previous valuation of UCB SA |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 40.18 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 40.18. The average price that FME.DE shares were previous bought at was EUR 45.9708. The current market price is -12.6% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 41,196 (USD $48,424) compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 726.6 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 726.6. The average price that ARGX.BR shares were previous bought at was EUR 585.67. The current market price is 24.1% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 163,878 (USD $192,632) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 153.942 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 153.942. The average price that AZN.L shares were previous bought at was GBP 132.331. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in AZN.L has fallen by GBP 1,463,895 (USD $1,958,781) compared to the previous valuation of AstraZeneca PLC |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 35.055 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 35.055. The average price that BAYN.DE shares were previous bought at was EUR 25.5091. The current market price is 37.4% higher than average price they were purchased at. The value of the holding in BAYN.DE has fallen by EUR 825,303 (USD $970,112) compared to the previous valuation of Bayer AG |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 107.2 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 107.2. The average price that BIM.PA shares were previous bought at was EUR 114.199. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 3,658 (USD $4,300) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 73.828 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 73.828. The average price that COLO-B.CO shares were previous bought at was DKK 83.2028. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 139,503 (USD $21,956) compared to the previous valuation of |
| DEMANT.CO - | HOLD | 0 @ DKK 28.6157 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 28.6157. The average price that DEMANT.CO shares were previous bought at was DKK 32.2794. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 17,954 (USD $2,826) compared to the previous valuation of however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 208.3 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 208.3. The average price that DIM.PA shares were previous bought at was EUR 192.964. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 26,039 (USD $30,608) compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 278.2 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 278.2. The average price that EL.PA shares were previous bought at was EUR 263.173. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 1,148,526 (USD $1,350,048) compared to the previous valuation of EssilorLuxottica SA |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 58.3 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 58.3. The average price that ERF.PA shares were previous bought at was EUR 57.6515. The current market price is 1.1% higher than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 4,195 (USD $4,931) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 66.7431 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 66.7431. The average price that ALC.SW shares were previous bought at was CHF 73.8693. The current market price is -9.6% lower than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 387,380 (USD $486,652) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 47.43 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 47.43. The average price that FRE.DE shares were previous bought at was EUR 42.6885. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in FRE.DE has fallen by EUR 401,866 (USD $472,378) compared to the previous valuation of Fresenius SE & Co KGaA |
| GALD.SW - | HOLD | 0 @ CHF 173.053 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 173.053. The average price that GALD.SW shares were previous bought at was CHF 132.226. The current market price is 30.9% higher than average price they were purchased at. The value of the holding in GALD.SW has fallen by CHF 711,632 (USD $893,999) compared to the previous valuation of |
| GMAB.CO - | HOLD | 0 @ DKK 265.88 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 265.88. The average price that GMAB.CO shares were previous bought at was DKK 209.088. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 193,715 (USD $30,488) compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 10.805 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 10.805. The average price that GRF.MC shares were previous bought at was EUR 10.6752. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 15,828 (USD $18,605) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 20.7387 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 20.7387. The average price that GSK.L shares were previous bought at was GBP 17.4295. The current market price is 19.0% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 505,434 (USD $676,302) compared to the previous valuation of GlaxoSmithKline PLC |
| HIK.L - | HOLD | 0 @ GBP 17.1769 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 17.1769. The average price that HIK.L shares were previous bought at was GBP 22.3835. The current market price is -23.3% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 9,140 (USD $12,230) compared to the previous valuation of however if the holding was sold on 2025-12-16 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.14205 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.14205. The average price that HLN.L shares were previous bought at was GBP 4.39824. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 464,473 (USD $621,493) compared to the previous valuation of Haleon PLC |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 120.6 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 120.6. The average price that IPN.PA shares were previous bought at was EUR 110.554. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 60,412 (USD $71,012) compared to the previous valuation of Ipsen SA |